# ADD The Ramco Cements

# In-line quarter; monetization of non-core assets remains key

Cement > Result Update > July 25, 2024

The Ramco Cements (Ramco)'s Q1FY25 EBITDA fell 7% YoY/23% QoQ to Rs3.2bn, broadly in line with consensus/our estimates. Blended EBITDA/t beat estimates, coming in at Rs733 (Emkay: Rs685) owing to higher than expected realization, on likely better States' sales mix. Ramco has increased its capacity target to 30mt by FY26 (26mt earlier), but retained its FY25 capex target of Rs12bn. Hence, high capex intensity will endure in FY26 too. The mgmt is looking to monetize non-core assets of ~Rs10bn within coming 12M – timely monetization will help Ramco fund growth capex/de-leverage its balance sheet; it will also be the key catalyst for a stock re-rating. Building-in lower realization, we cut FY25-26E EBITDA by 6-10% with unchanged Jun-25E TP of Rs865/sh based on 13x EV/E (earlier 12.5x), after quarterly roll-over. We retain ADD.

<b>The Ramco Cements</b>	: Financial S	Snapshot (O	Consolidate	ed)	
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	81,573	93,764	94,617	104,035	116,505
EBITDA	11,856	15,646	15,528	19,218	23,198
Adj. PAT	3,145	3,599	3,107	5,341	8,257
Adj. EPS (Rs)	13.3	15.2	13.1	22.6	34.9
EBITDA margin (%)	14.5	16.7	16.4	18.5	19.9
EBITDA growth (%)	(8.1)	32.0	(0.8)	23.8	20.7
Adj. EPS growth (%)	(64.3)	14.4	(13.7)	71.9	54.6
RoE (%)	4.7	5.1	4.2	6.9	9.9
RoIC (%)	5.6	6.3	5.5	7.1	8.7
P/E (x)	60.2	52.6	60.9	35.4	22.9
EV/EBITDA (x)	19.6	15.2	15.5	12.5	10.2
P/B (x)	2.8	2.6	2.5	2.4	2.2
FCFF yield (%)	(1.5)	0.0	0.8	1.9	3.5

Source: Company, Emkay Research

## **Result Summary**

Ramco posted muted volume growth of 1% YoY/decline of 21% QoQ to 4.29mt, implying utilization of 77% in Q1FY25 (fell by 200bps YoY/1,900bps QoQ). Blended realization surprised positively, with a decline of 8% YoY/1.6% QoQ to Rs4,792 (a decline of Rs76/t sequentially) vs our estimate of Rs4,722, owing to better States' sales mix. The company targets 30mt cement capacity by FY26 (vs 26mt earlier). Along with the ongoing clinker/cement capacity addition of 3.15mt/1.5mt for Kurnool line-2, Ramco has suggested de-bottlenecking the current facilities and adding grinding capacities at existing locations with minimal capex. FY25 capex guidance remains unchanged at Rs12bn (Q1 spend stood at Rs2.8bn). Accordingly, we expect high and back-ended capex in FY26E. Net debt increased by Rs2.8bn QoQ to ~Rs50bn as of Jun-24.

What we liked: Better than expected realization

What we did not like: Lower than industry volume growth; increase in net debt

**Key catalyst:** The company has taken effective steps to monetize certain non-core assets, worth ~Rs10bn, in the next 12 months. Timely monetization of non-core assets will help it fund growth capex/de-leverage its balance sheet and act as the key trigger for a stock re-rating. We have not factored non-core asset monetization in our estimates.

**Key takeaways from Q1FY25 results:** i) In Kolimigundla, TPP of 18MW was commissioned in Jul-24, and trials are being done. Railway siding will be commissioned during Sep-24. The company has started seeing synergies in the cost for usage of limestone mined from the lands purchased from Prism. 2) Line 2 in Kolimigundla comprising of 3.15mt clinker capacity and 1.5mt cement capacity with WHRS capacity of 15MW is scheduled for commissioning by 4QFY26. 3) The WHRS plant in Ramasamy Raja Nagar, with 10MW capacity, is up for commissioning by 4QFY25. 4) 50% of the mining land for the new project in Karnataka has been acquired so far.

**TARGET PRICE (Rs): 865** 

Target Price – 12M	Jun-25
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	8.0
CMP (25-Jul-24) (Rs)	800.9
Stock Data	Ticker
52-week High (Rs)	1,058
52-week Low (Rs)	700
Shares outstanding (mn)	236.3
Market-cap (Rs bn)	189
Market-cap (USD mn)	2,261
Net-debt, FY25E (Rs mn)	50,843
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	1,017.4
ADTV-3M (USD mn)	12.2
Free float (%)	-
Nifty-50	24,406
INR/USD	83.7
Shareholding, Jun-24	
Promoters (%)	42.3
FPIs/MFs (%)	7.4/31.1

Price Perform	ance		
(%)	1M	ЗМ	12M
Absolute	(5.9)	1.5	(10.8)
Rel. to Nifty	(8.6)	(6.2)	(28.1)



Dharmesh Shah

dharmesh.shah@emkayglobal.com +91 22 6612 1255



# **Quarterly Analysis**

# Exhibit 1: Actual vs. Estimates (Q1FY25)

(Pc mn)	Actual	Esti	mates	Varia	tion (%)	Commont
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Net sales	20,884	21,259	21,590	(1.8)	(3.3)	
EBITDA	3,194	3,084	3,118	3.6	2.4	Broadly in-line quarter
PAT	355	371	480	(4.4)	(26.0)	
Volumes (mt)	4.4	4.5		(3.2)		
Blended realization (Rs/ton)	4,792	4,722		1.5		
EBITDA (Rs/ton)	733	685		7.0		

Source: Bloomberg, Emkay Research

## Exhibit 2: Quarterly financial highlights

		3QFY24	4QFY24	1QFY25	YoY (%)	QoQ (%)
22,411	23,293	21,061	26,733	20,884	(6.8)	(21.9)
18,996	19,307	17,108	22,562	17,690	(6.9)	(21.6)
3,268	4,419	3,280	6,213	3,638	11.3	(41.5)
7,559	6,262	5,536	6,192	5,666	(25.0)	(8.5)
4,577	4,724	4,293	5,940	4,638	1.3	(21.9)
1,266	1,385	1,369	1,245	1,367	8.0	9.9
2,327	2,517	2,629	2,973	2,381	2.3	(19.9)
3,415	3,986	3,954	4,171	3,194	(6.5)	(23.4)
1,479	1,574	1,655	1,651	1,667	12.7	1.0
1,936	2,412	2,299	2,520	1,527	(21.1)	(39.4)
79	135	70	140	85	7.7	(39.3)
934	1,165	1,019	1,038	1,131	21.1	9.0
1,081	1,382	1,350	1,623	482	(55.4)	(70.3)
292	369	416	409	127	(56.6)	(69.0)
789	1,013	934	1,214	355	(55.0)	(70.8)
789	1,013	934	1,214	355	(55.0)	(70.8)
-	-	-	-	-	NA	NA
789	1,013	934	1,214	355	(55.0)	(70.8)
3.3	4.3	4.0	5.1	1.5	(55.0)	(70.7)
1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	YoY (bps)	QoQ (bps)
15.2	17.1	18.8	15.6	15.3	0.4	(2.0)
8.6	10.4	10.9	9.4	7.3	(15.3)	(22.4)
4.8	5.9	6.4	6.1	2.3	(52.2)	(62.0)
3.5	4.3	4.4	4.5	1.7	(51.7)	(62.6)
27.0	26.7	30.8	25.2	26.3		
	3,268 7,559 4,577 1,266 2,327 <b>3,415</b> 1,479 1,936 79 934 1,081 292 789 789 789 789 789 3.3 10FY24 10FY24 15.2 8.6 4.8 3.5	3,268 4,419   7,559 6,262   4,577 4,724   1,266 1,385   2,327 2,517   3,415 3,986   1,479 1,574   1,936 2,412   79 135   934 1,165   1,081 1,382   292 369   789 1,013   789 1,013   3.3 4.3   IQFY24   15.2 17.1   8.6 10.4   4.8 5.9   3.5 4.3	3,268     4,419     3,280       7,559     6,262     5,536       4,577     4,724     4,293       1,266     1,385     1,369       2,327     2,517     2,629       3,415     3,986     3,954       1,479     1,574     1,655       1,936     2,412     2,299       79     135     70       934     1,165     1,019       1,081     1,382     1,350       292     369     416       789     1,013     934       789     1,013     934       789     1,013     934       3.3     4.3     4.0       TOP       10FY24     20FY24     30FY24       10.9     4.8     5.9     6.4       3.5     4.3     4.4	A     A     A     A       3,268     4,419     3,280     6,213       7,559     6,262     5,536     6,192       4,577     4,724     4,293     5,940       1,266     1,385     1,369     1,245       2,327     2,517     2,629     2,973       3,415     3,986     3,954     4,171       1,479     1,574     1,655     1,651       1,936     2,412     2,299     2,520       79     135     70     140       934     1,165     1,019     1,038       1,081     1,382     1,350     1,623       292     369     416     409       789     1,013     934     1,214       789     1,013     934     1,214       789     1,013     934     1,214       3.3     4.3     4.0     5.1       10     9.4     3.6     5.6       8.6     10.4     10.9     9.4 <t< td=""><td>3,268   4,419   3,280   6,213   3,638     7,559   6,262   5,536   6,192   5,666     4,577   4,724   4,293   5,940   4,638     1,266   1,385   1,369   1,245   1,367     2,327   2,517   2,629   2,973   2,381     3,415   3,986   3,954   4,171   3,194     1,479   1,574   1,655   1,651   1,667     1,936   2,412   2,299   2,520   1,527     79   135   70   140   85     934   1,165   1,019   1,038   1,131     1,081   1,382   1,350   1,623   482     292   369   416   409   127     789   1,013   934   1,214   355     789   1,013   934   1,214   355     789   1,013   934   1,214   355     3.3   4.3   4.0   5.1   1.5     10FY24   2QFY24   3QFY24   4QFY24   <t< td=""><td>3,268   4,419   3,280   6,213   3,688   11.3     7,559   6,262   5,536   6,192   5,666   (25.0)     4,577   4,724   4,293   5,940   4,638   1.3     1,266   1,385   1,369   1,245   1,367   8.0     2,327   2,517   2,629   2,973   2,381   2.3     3,415   3,986   3,954   4,171   3,194   (6.5)     1,479   1,574   1,655   1,651   1,667   12.7     1,936   2,412   2,299   2,520   1,527   (21.1)     79   135   70   140   85   7.7     934   1,165   1,019   1,038   1,131   21.1     1,081   1,382   1,350   1,623   482   (55.4)     292   369   416   409   127   (56.6)     789   1,013   934   1,214   355   (55.0)     789   1,013   934   1,214   355   (55.0)     3.3   4.3</td></t<></td></t<>	3,268   4,419   3,280   6,213   3,638     7,559   6,262   5,536   6,192   5,666     4,577   4,724   4,293   5,940   4,638     1,266   1,385   1,369   1,245   1,367     2,327   2,517   2,629   2,973   2,381     3,415   3,986   3,954   4,171   3,194     1,479   1,574   1,655   1,651   1,667     1,936   2,412   2,299   2,520   1,527     79   135   70   140   85     934   1,165   1,019   1,038   1,131     1,081   1,382   1,350   1,623   482     292   369   416   409   127     789   1,013   934   1,214   355     789   1,013   934   1,214   355     789   1,013   934   1,214   355     3.3   4.3   4.0   5.1   1.5     10FY24   2QFY24   3QFY24   4QFY24 <t< td=""><td>3,268   4,419   3,280   6,213   3,688   11.3     7,559   6,262   5,536   6,192   5,666   (25.0)     4,577   4,724   4,293   5,940   4,638   1.3     1,266   1,385   1,369   1,245   1,367   8.0     2,327   2,517   2,629   2,973   2,381   2.3     3,415   3,986   3,954   4,171   3,194   (6.5)     1,479   1,574   1,655   1,651   1,667   12.7     1,936   2,412   2,299   2,520   1,527   (21.1)     79   135   70   140   85   7.7     934   1,165   1,019   1,038   1,131   21.1     1,081   1,382   1,350   1,623   482   (55.4)     292   369   416   409   127   (56.6)     789   1,013   934   1,214   355   (55.0)     789   1,013   934   1,214   355   (55.0)     3.3   4.3</td></t<>	3,268   4,419   3,280   6,213   3,688   11.3     7,559   6,262   5,536   6,192   5,666   (25.0)     4,577   4,724   4,293   5,940   4,638   1.3     1,266   1,385   1,369   1,245   1,367   8.0     2,327   2,517   2,629   2,973   2,381   2.3     3,415   3,986   3,954   4,171   3,194   (6.5)     1,479   1,574   1,655   1,651   1,667   12.7     1,936   2,412   2,299   2,520   1,527   (21.1)     79   135   70   140   85   7.7     934   1,165   1,019   1,038   1,131   21.1     1,081   1,382   1,350   1,623   482   (55.4)     292   369   416   409   127   (56.6)     789   1,013   934   1,214   355   (55.0)     789   1,013   934   1,214   355   (55.0)     3.3   4.3

Source: Company, Emkay Research

Exhibit 3: Quarterly analysis on a per-ton basis

(Rs/ton)	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	YoY (%)	QoQ (%)
Total volumes (mt)	4.3	4.6	4.0	5.5	4.4	1.3	(20.6)
Blended Realization	5,212	5,053	5,272	4,869	4,792	(8.1)	(1.6)
Raw Material cost	760	959	821	1,132	835	9.8	(26.2)
Power & Fuel cost	1,758	1,358	1,386	1,128	1,300	(26.0)	15.3
Freight cost	1,064	1,025	1,075	1,082	1,064	(0.0)	(1.6)
Staff cost	294	300	343	227	314	6.6	38.4
Other expenditure	541	546	658	541	546	0.9	0.9
Operating cost	4,418	4,188	4,282	4,109	4,059	(8.1)	(1.2)
Blended EBITDA	794	865	990	760	733	(7.7)	(3.5)

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 07/28/2024 04:55 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 4: We cut our EBITDA estimates by 6-11% for FY25-26

Earnings revision		FY25E		FY26E				
Lannings revision	Old	New	Change (%)	Old	New	Change (%)		
Revenue (Rs mn)	100,377	94,617	(5.7)	110,044	104,035	(5.5)		
EBITDA (Rs mn)	17,426	15,528	(10.9)	20,370	19,218	(5.7)		
PAT (Rs mn)	4,554	3,107	(31.8)	6,218	5,341	(14.1)		

Source: Emkay Research

# Exhibit 5: We maintain our ADD rating on Ramco, with unchanged TP of Rs865/share, based on Jun-26E EV/E of 13x

EV/E valuation	
Jun-26E EBITDA (Rs bn)	19.6
EV/E (x)	13.0
Enterprise Value (Rs bn)	255
Net debt (Jun-25E; Rs bn)	51
Equity value (Rs bn)	204
No. of shares (mn)	236
Jun-25E Target Price (Rs/share)	865

Source: Emkay Research

## **Exhibit 6: Annual Analysis**

Kou Accumptions	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E	CAGR	(%)
Key Assumptions	FTIS	FT20	F¥21	FY22	F123	F¥24	FT25E	FT20E	FT2/E	FY19-24	FY24-27E
Capacity (mt)	16.7	18.8	19.4	19.4	22.0	23.0	24.0	25.5	30.0	6.6	9.3
Volumes (mt)	11.1	11.2	10.0	11.0	14.8	18.4	19.4	20.8	22.6	10.6	7.2
Utilization (%)	67	60	51	57	67	80	81	81	75		
Blended Realization (Rs/ton)	4,619	4,788	5,278	5,392	5,465	5,097	4,875	5,010	5,147	2.0	0.3
EBITDA/ton (Rs)	959	1,024	1,560	1,168	800	851	800	925	1,025	(2.4)	6.4
P&L (Rs bn)											
Revenue	52	54	53	60	82	94	95	104	117	12.7	7.5
EBITDA	11	11	16	13	12	16	16	19	21	8.0	10.1
Adj. Net Profit	5	6	8	9	3	4	3	5	8	(7.5)	31.9
Balance Sheet (Rs bn)											
Equity	45	50	57	66	69	72	75	80	87		
Net Debt	15	29	30	38	44	48	51	51	48		
Net Debt:EBITDA (x)	1.4	2.6	1.9	2.9	3.7	3.1	3.3	2.7	2.3		
Net Debt:Equity (x)	0.3	0.6	0.5	0.6	0.6	0.7	0.7	0.6	0.6		
Cash Flow (Rs bn)											
OCF before WC change	9	10	13	10	10	11	10	13	16		
Change in WC	(1)	(3)	5	(0)	3	4	(0)	(0)	(0)		
Capex	(12)	(19)	(18)	(18)	(18)	(19)	(12)	(12)	(12)		
FCF	(4)	(12)	1	(8)	(5)	(4)	(2)	0	4		
Return ratios (%)											
RoE	12.3	12.7	15.0	14.3	4.7	5.1	4.2	6.9	9.9		
RoCE	8.7	8.2	9.1	9.4	4.1	5.2	4.8	6.3	8.0		
RoIC	10.4	10.8	12.4	13.7	5.9	6.6	5.8	7.3	8.9		
Valuations (x)											
PER							60.9	35.4	22.9		
EV/EBITDA							15.4	12.6	10.4		
EV/ton (US\$)							120	113	95		

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 07/28/2024 04:55 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 7: Annual analysis on a per-ton basis

(Rs/ton)	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Blended realization	4,619	4,788	5,278	5,392	5,465	5,097	4,875	5,010	5,147
YoY (%)	(2.3)	3.7	10.2	2.1	1.4	(6.7)	(4.3)	2.8	2.7
Raw material costs	761	780	867	806	906	934	913	919	939
Power & fuel costs	950	938	796	1,257	1,796	1,386	1,237	1,222	1,238
Freight costs	1,068	1,016	1,028	1,099	1,081	1,062	1,070	1,081	1,086
Staff costs	304	340	420	394	326	300	298	304	304
Other expenses	599	713	630	711	595	564	557	559	555
Operating Costs	3,682	3,786	3,741	4,266	4,704	4,246	4,075	4,084	4,122
YoY (%)	3.1	2.8	(1.2)	14.0	10.3	(9.7)	(4.0)	0.2	0.9
Blended EBITDA	959	1,024	1,560	1,168	800	851	800	925	1,025
YoY (%)	(18.8)	6.8	52.4	(25.2)	(31.5)	6.3	(5.9)	15.7	10.7

Source: Company, Emkay Research



Exhibit 9: One-year forward EV/EBITDA



Source: Bloomberg, Emkay Research

Source: Bloomberg, Emkay Research

This report is intended for team emkay @whitemarguesolutions com use and downloaded at 07/28/2024 04:55 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# India Equity Research | Result Update

# The Ramco Cements: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	81,573	93,764	94,617	104,035	116,505
Revenue growth (%)	35.9	14.9	0.9	10.0	12.0
EBITDA	11,856	15,646	15,528	19,218	23,198
EBITDA growth (%)	(8.1)	32.0	(0.8)	23.8	20.7
Depreciation & Amortization	5,060	6,463	6,772	7,305	7,820
EBIT	6,796	9,183	8,756	11,913	15,378
EBIT growth (%)	(23.5)	35.1	(4.6)	36.1	29.1
Other operating income	569	0	0	0	(
Other income	329	389	393	401	409
Financial expense	2,405	4,155	4,497	4,643	4,676
PBT	4,720	5,417	4,653	7,671	11,111
Extraordinary items	0	0	0	0	(
Taxes	1,300	1,481	1,210	1,995	2,889
Minority interest	2	(35)	(35)	(35)	(35
Income from JV/Associates	(272)	(370)	(370)	(370)	(
Reported PAT	3,145	3,599	3,107	5,341	8,257
PAT growth (%)	(64.3)	14.4	(13.7)	71.9	54.0
Adjusted PAT	3,145	3,599	3,107	5,341	8,257
Diluted EPS (Rs)	13.3	15.2	13.1	22.6	34.9
Diluted EPS growth (%)	(64.3)	14.4	(13.7)	71.9	54.6
DPS (Rs)	2.0	2.5	1.6	2.8	4.4
Dividend payout (%)	15.0	16.4	12.5	12.5	12.5
EBITDA margin (%)	14.5	16.7	16.4	18.5	19.9
EBIT margin (%)	8.3	9.8	9.3	11.5	13.2
Effective tax rate (%)	27.5	27.3	26.0	26.0	26.0
NOPLAT (pre-IndAS)	4,924	6,671	6,479	8,816	11,380
Shares outstanding (mn)	236.3	236.3	236.3	236.3	236.3

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	236	236	236	236	236
Reserves & Surplus	68,374	72,143	74,861	79,535	86,759
Net worth	68,611	72,379	75,098	79,771	86,996
Minority interests	70	36	36	36	36
Deferred tax liability (net)	9,250	10,268	10,268	10,268	10,268
Total debt	45,213	49,585	50,902	52,830	51,641
Total liabilities & equity	123,144	132,268	136,304	142,905	148,941
Net tangible fixed assets	100,383	118,859	126,745	133,568	139,449
Net intangible assets	670	670	670	670	670
Net ROU assets	209	219	219	219	219
Capital WIP	19,269	13,292	10,634	8,507	6,806
Goodwill	0	0	0	0	0
Investments [JV/Associates]	4,016	4,467	4,467	4,467	4,467
Cash & equivalents	1,703	1,369	60	1,727	3,494
Current assets (ex-cash)	19,675	23,820	22,884	25,259	29,195
Current Liab. & Prov.	22,779	30,428	29,375	31,511	35,359
NWC (ex-cash)	(3,105)	(6,608)	(6,490)	(6,252)	(6,164)
Total assets	123,144	132,268	136,304	142,905	148,941
Net debt	43,510	48,216	50,843	51,103	48,147
Capital employed	123,144	132,268	136,304	142,905	148,941
Invested capital	98,156	113,140	121,143	128,204	134,174
BVPS (Rs)	290.4	306.3	317.8	337.6	368.2
Net Debt/Equity (x)	0.6	0.7	0.7	0.6	0.6
Net Debt/EBITDA (x)	3.7	3.1	3.3	2.7	2.1
Interest coverage (x)	3.0	2.3	2.0	2.7	3.4
RoCE (%)	6.0	7.5	6.8	8.8	10.8

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
РВТ	4,720	5,417	4,653	7,671	11,111
Others (non-cash items)	(253)	(209)	0	0	0
Taxes paid	(327)	(428)	(1,210)	(1,995)	(2,889)
Change in NWC	2,510	3,657	(118)	(238)	(89)
Operating cash flow	14,114	19,055	13,865	16,650	20,255
Capital expenditure	(17,635)	(19,143)	(12,000)	(12,000)	(12,000)
Acquisition of business	523	(175)	0	0	0
Interest & dividend income	74	92	393	401	409
Investing cash flow	(16,940)	(19,109)	(11,607)	(11,599)	(11,591)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	5,790	4,258	1,318	1,928	(1,189)
Payment of lease liabilities	0	0	0	0	0
Interest paid	(2,335)	(4,065)	(4,497)	(4,643)	(4,676)
Dividend paid (incl tax)	(710)	(473)	(388)	(668)	(1,032)
Others	0	0	0	0	0
Financing cash flow	2,745	(280)	(3,567)	(3,383)	(6,897)
Net chg in Cash	(81)	(334)	(1,309)	1,668	1,767
OCF	14,114	19,055	13,865	16,650	20,255
Adj. OCF (w/o NWC chg.)	11,604	15,398	13,983	16,887	20,343
FCFF	(3,521)	(87)	1,865	4,649	8,255
FCFE	2,269	4,170	3,183	6,577	7,066
OCF/EBITDA (%)	119.0	121.8	89.3	86.6	87.3
FCFE/PAT (%)	72.1	115.9	102.4	123.1	85.6
FCFF/NOPLAT (%)	(71.5)	(1.3)	28.8	52.7	72.5

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key R	atios				
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	60.2	52.6	60.9	35.4	22.9
P/CE(x)	23.1	18.8	19.2	15.0	11.8
P/B (x)	2.8	2.6	2.5	2.4	2.2
EV/Sales (x)	2.9	2.5	2.5	2.3	2.0
EV/EBITDA (x)	19.6	15.2	15.5	12.5	10.2
EV/EBIT(x)	34.2	25.9	27.4	20.2	15.4
EV/IC (x)	2.4	2.1	2.0	1.9	1.8
FCFF yield (%)	(1.5)	0.0	0.8	1.9	3.5
FCFE yield (%)	1.0	1.8	1.3	2.7	3.0
Dividend yield (%)	0.2	0.3	0.2	0.4	0.5
DuPont-RoE split					
Net profit margin (%)	3.9	3.8	3.3	5.1	7.1
Total asset turnover (x)	0.7	0.7	0.7	0.7	0.8
Assets/Equity (x)	1.8	1.8	1.8	1.8	1.8
RoE (%)	4.7	5.1	4.2	6.9	9.9
DuPont-RoIC					
NOPLAT margin (%)	6.0	7.1	6.8	8.5	9.8
IC turnover (x)	0.9	0.9	0.8	0.8	0.9
RoIC (%)	5.6	6.3	5.5	7.1	8.7
Operating metrics					
Core NWC days	(13.9)	(25.7)	(25.0)	(21.9)	(19.3)
Total NWC days	(13.9)	(25.7)	(25.0)	(21.9)	(19.3)
Fixed asset turnover	0.6	0.6	0.5	0.5	0.6
Opex-to-revenue (%)	69.0	65.0	64.9	63.2	61.8

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 07/28/2024 04:55 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
01-Jul-24	857	865	Add	Dharmesh Shah
10-Jun-24	877	865	Add	Dharmesh Shah
01-Jun-24	742	865	Add	Dharmesh Shah
22-May-24	774	865	Add	Dharmesh Shah
01-Apr-24	846	950	Reduce	Dharmesh Shah
04-Mar-24	848	950	Reduce	Dharmesh Shah
09-Feb-24	902	950	Reduce	Dharmesh Shah
05-Jan-24	1,028	1,080	Reduce	Dharmesh Shah
30-Nov-23	994	990	Reduce	Dharmesh Shah
30-Nov-23	994	990	Hold	Dharmesh Shah
09-Nov-23	1,022	990	Hold	Dharmesh Shah
28-Sep-23	909	880	Hold	Dharmesh Shah
18-Sep-23	886	880	Hold	Dharmesh Shah
07-Aug-23	874	880	Hold	Dharmesh Shah
03-Jun-23	915	880	Hold	Dharmesh Shah
19-May-23	844	880	Hold	Dharmesh Shah
04-May-23	754	715	Hold	Dharmesh Shah
02-Mar-23	726	715	Hold	Dharmesh Shah
07-Feb-23	701	715	Hold	Dharmesh Shah
05-Feb-23	683	670	Hold	Dharmesh Shah
29-Dec-22	700	670	Hold	Dharmesh Shah
05-Dec-22	692	670	Hold	Dharmesh Shah
09-Nov-22	704	670	Hold	Dharmesh Shah
05-Nov-22	727	710	Hold	Dharmesh Shah
04-Oct-22	757	710	Hold	Dharmesh Shah
04-Sep-22	748	710	Hold	Dharmesh Shah
01-Aug-22	752	710	Hold	Dharmesh Shah
04-Jul-22	645	650	Hold	Dharmesh Shah
28-Jun-22	628	650	Hold	Dharmesh Shah
23-May-22	680	770	Hold	Dharmesh Shah
16-Mar-22	750	800	Hold	Dharmesh Shah
25-Jan-22	861	1,050	Buy	Dharmesh Shah
31-Dec-21	1,004	1,200	Buy	Dharmesh Shah
02-Dec-21	951	1,200	Buy	Dharmesh Shah
26-Oct-21	1,015	1,200	Buy	Dharmesh Shah
05-Sep-21	1,047	1,175	Hold	Dharmesh Shah
28-Jul-21	1,041	1,175	Hold	Dharmesh Shah

Source: Company, Emkay Research

## **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 07/28/2024 04:55 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. It is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 07/28/2024 04:55 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup>An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of July 25, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of July 25, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the July 25, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

#### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 07/28/2024 04:55 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### OTHER DISCLAIMERS AND DISCLOSURES:

# Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.